These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 9577959)

  • 1. Sulfonylureas and cardiovascular mortality in diabetes: a class effect?
    Wascher TC
    Circulation; 1998 Apr; 97(14):1427-8. PubMed ID: 9577959
    [No Abstract]   [Full Text] [Related]  

  • 2. Comment on: Evans JMM, Ogston SA, Emslie-Smith A, Morris AD (2006) risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 49:930-936.
    Tayek JA
    Diabetologia; 2006 Nov; 49(11):2807-8. PubMed ID: 16955252
    [No Abstract]   [Full Text] [Related]  

  • 3. Insulin as a first-line therapy in type 2 diabetes: should the use of sulfonylureas be halted?
    Standl E; Schnell O
    Diabetes Care; 2008 Feb; 31 Suppl 2():S136-9. PubMed ID: 18227474
    [No Abstract]   [Full Text] [Related]  

  • 4. Comment on: Evans JMM, Ogston SA, Emslie-Smith A, Morris AD (2006) Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 49:930-936.
    Raccah D
    Diabetologia; 2007 May; 50(5):1109-10; author reply 1111. PubMed ID: 17351766
    [No Abstract]   [Full Text] [Related]  

  • 5. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin.
    Evans JM; Ogston SA; Emslie-Smith A; Morris AD
    Diabetologia; 2006 May; 49(5):930-6. PubMed ID: 16525843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Newer Sulfonylureas Not Associated with Increased Mortality, MIs, or Strokes.
    Barry HC
    Am Fam Physician; 2016 Sep; 94(5):386. PubMed ID: 27583428
    [No Abstract]   [Full Text] [Related]  

  • 7. Interplay of diabetes and coronary heart disease on cardiovascular mortality.
    Boccara F; Cohen A
    Heart; 2004 Dec; 90(12):1371-3. PubMed ID: 15547003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antihyperglycemic treatment in diabetics with coronary disease: increased metformin-associated mortality over a 5-year follow-up.
    Fisman EZ; Tenenbaum A; Benderly M; Goldbourt U; Behar S; Motro M
    Cardiology; 1999; 91(3):195-202. PubMed ID: 10516414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of an antidiabetic treatment with sulfonylurea drugs on long-term survival after acute myocardial infarction in patients with type 2 diabetes. The LAngendreer Myocardial infarction and Blood glucose in Diabetic patients Assessment (LAMBDA).
    Meier JJ; Deifuss S; Klamann A; Schmiegel W; Nauck MA;
    Exp Clin Endocrinol Diabetes; 2003 Sep; 111(6):344-50. PubMed ID: 14520601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials.
    Lamanna C; Monami M; Marchionni N; Mannucci E
    Diabetes Obes Metab; 2011 Mar; 13(3):221-8. PubMed ID: 21205121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular disease and intensive glucose lowering in type 2 diabetes.
    Younis N; Soran H; Hassanein M
    QJM; 2009 Apr; 102(4):293-6. PubMed ID: 19147659
    [No Abstract]   [Full Text] [Related]  

  • 12. [Effect of insulin and sulfonylurea derivatives on chronic intravascular microcoagulation of the blood in diabetes mellitus].
    Velikov VK; Galkina AK; Bokarev IN; Frolova AI; Shubina OI
    Sov Med; 1985; (9):91-3. PubMed ID: 3906934
    [No Abstract]   [Full Text] [Related]  

  • 13. Glipizide for reversal of early diabetic microangiopathy.
    N Engl J Med; 1984 May; 310(21):1389-90. PubMed ID: 6717514
    [No Abstract]   [Full Text] [Related]  

  • 14. Hypoglycaemia seriousness and weight gain as determinants of cardiovascular disease outcomes among sulfonylurea users.
    Nunes AP; Iglay K; Radican L; Engel SS; Yang J; Doherty MC; Dore DD
    Diabetes Obes Metab; 2017 Oct; 19(10):1425-1435. PubMed ID: 28497592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diabetes, coronary heart disease and sulphonylureas-not the final word.
    Betteridge DJ; Close L
    Eur Heart J; 2000 May; 21(10):790-2. PubMed ID: 10781346
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial.
    Vaccaro O; Masulli M; Nicolucci A; Bonora E; Del Prato S; Maggioni AP; Rivellese AA; Squatrito S; Giorda CB; Sesti G; Mocarelli P; Lucisano G; Sacco M; Signorini S; Cappellini F; Perriello G; Babini AC; Lapolla A; Gregori G; Giordano C; Corsi L; Buzzetti R; Clemente G; Di Cianni G; Iannarelli R; Cordera R; La Macchia O; Zamboni C; Scaranna C; Boemi M; Iovine C; Lauro D; Leotta S; Dall'Aglio E; Cannarsa E; Tonutti L; Pugliese G; Bossi AC; Anichini R; Dotta F; Di Benedetto A; Citro G; Antenucci D; Ricci L; Giorgino F; Santini C; Gnasso A; De Cosmo S; Zavaroni D; Vedovato M; Consoli A; Calabrese M; di Bartolo P; Fornengo P; Riccardi G; ;
    Lancet Diabetes Endocrinol; 2017 Nov; 5(11):887-897. PubMed ID: 28917544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sulphonylurea-metformin combination therapy, cardiovascular disease and all-cause mortality: the Fremantle Diabetes Study.
    Sillars B; Davis WA; Hirsch IB; Davis TM
    Diabetes Obes Metab; 2010 Sep; 12(9):757-65. PubMed ID: 20649627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Therapeutic value of a new original oral antidiabetic with vascular action: gliclazide (SE-1702)].
    Canivet J
    Therapeutique; 1972; 48(7):457-62. PubMed ID: 4640264
    [No Abstract]   [Full Text] [Related]  

  • 19. Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials.
    Monami M; Genovese S; Mannucci E
    Diabetes Obes Metab; 2013 Oct; 15(10):938-53. PubMed ID: 23594109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular disease and oral agent glucose-lowering therapies in the management of type 2 diabetes.
    Home P
    Diabetes Technol Ther; 2012 Jun; 14 Suppl 1():S33-42. PubMed ID: 22650223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.